Data Year:

For its 2025 fiscal year, MERCK & CO INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Robert M. Davis
Chairman, Chief Executive Officer and President
Total Compensation $20,112,702 View details Pay Rank By Title In Biotechnology industry #30 View more
Sanat Chattopadhyay
Executive Vice President and President, Merck Manufacturing Division
Total Compensation $5,117,344 View details Pay Rank By Title In Biotechnology industry #48 View more
Jennifer Zachary
Executive Vice President and General Counsel
Total Compensation $5,606,261 View details Pay Rank By Title In Biotechnology industry #41 View more
Dean Li M.D., Ph.D.
Executive Vice President and President, Merck Research Laboratories
Total Compensation $8,494,042 View details Pay Rank By Title In Biotechnology industry #23 View more
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Total Compensation $6,981,321 View details Pay Rank By Title In Biotechnology industry #28 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at MERCK & CO INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. MERCK & CO INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. MERCK & CO INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Robert M. Davis
Chairman, Chief Executive Officer and President
Total Cash $3,971,802 Equity $15,482,842 Other $658,058 $20,112,702
Sanat Chattopadhyay
Executive Vice President and President, Merck Manufacturing Division
Total Cash $1,902,880 Equity $3,023,265 Other $191,199 $5,117,344
Jennifer Zachary
Executive Vice President and General Counsel
Total Cash $2,057,966 Equity $3,435,573 Other $112,722 $5,606,261
Dean Li M.D., Ph.D.
Executive Vice President and President, Merck Research Laboratories
Total Cash $2,828,640 Equity $5,496,855 Other $168,547 $8,494,042
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Total Cash $2,273,014 Equity $4,580,689 Other $127,618 $6,981,321
For its 2025 fiscal year, MERCK & CO INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Robert M. Davis CEO Pay $20,797,845 Median Employee Pay $108,614 CEO Pay Ratio 191:1
For its 2025 fiscal year, MERCK & CO INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Christine E. Seidman, M.D. Total Cash $385,000
Douglas M. Baker, Jr. Total Cash $350,000
Inge G. Thulin Total Cash $340,000
Kathy J. Warden Total Cash $340,000
Mary Ellen Coe Total Cash $340,000
Pamela J. Craig Total Cash $405,000
Patricia F. Russo Total Cash $365,000
Paul B. Rothman, M.D. Total Cash $405,000
Risa J. Lavizzo-Mourey, M.D. Total Cash $340,000
Stephen L. Mayo, Ph.D. Total Cash $350,000
Surendralal L. Karsanbhai Total Cash $405,000
Thomas H. Glocer Total Cash $415,000
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.